Skip to main content
OpenTrials
Completed

NCT Number: NCT02822638

Cohort of STEMI Patients

Ischemic heart disease is the leading cause of mortality in industrialized countries. ST elevated acute myocardial infarction is one of its most frequent and deadly manifestation. In the last 20 years, STEMI mortality has been reduced by 50% with the advent of timely reperfusion (primary percutaneous intervention) and significant progression in pharmacologic intervention.

However, death and heart failure incidence after STEMI remain elevated: up to 20% at one year.

Also, therapeutic management following international guidelines is standardized toward a "one-size fits all" therapeutic management.

In order to continue improving myocardial infarction outcomes, there is a need to better understand and individualize therapeutic targets such myocardial reperfusion injury, post reperfusion inflammation, adverse left ventricular (LV) remodeling ….

This knowledge will allow us to propose new therapeutic strategies and in the long run strive towards personalized medicine.

The aim objective of this cohort of STEMI patients is to identify new biological markers of injury and prognosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myocardial Infarction Cardiovascular Diseases Heart Diseases Infarction Ischemia Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms ST Elevation Myocardial Infarction Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Cardiovasculaire Louis Pradel 28, Avenue du Doyen Lépine

Bron, 69677, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age> 18 years
  • Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead ECG.
  • Primary PCI within 12 hours of symptoms onset.

Exclusion criteria

  • Diagnosis of STEMI not confirmed by angiography
  • Refusal to participate in the study or to sign the consent
  • Inability to give information to the subject about the study
  • Lack of medical social coverage
  • Deprivation of civil rights

Treatment and study plan

STEMI PATIENT Cohort

Other

PCI

Primary outcomes

  1. Change in Troponin

    Time frame: Day 0

    Dosage of Troponin at hospital admission and 4 hours after Percutaneous coronary intervention (PCI)

  2. Change in Creatine Kinase

    Time frame: Day 0

    Dosage of Creatine Kinase at hospital admission and 4 hours after PCI

Secondary outcomes

  1. New York Heart Association (NYHA) Class

    Time frame: at admission (Day 0)

  2. Left ventricular ejection fraction (LVEF)

    Time frame: 24 hours after PCI (Day 1)

    LVEF measured by echocardiography

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: STEMI

Important dates

Study start
2009
Primary completion
2016
Study completion
2016
First posted
Jul 4, 2016
Registry last updated
Jul 4, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.